drugset / Trial / NCT00720434
A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to further assess the potency of PF-00868554, an HCV polymerase inhibitor, in subjects chronically infected with HCV by evaluating the antiviral activity of PF-00868554 in combination with current standard of care therapy, pegylated interferon-alpha2a (PEGASYS) and ribavirin (COPEGUS).
Timeline
- Start
- 2008-08
- Primary completion
- 2010-03
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Filibuvir | Small molecule | 200 mg | — |
| Subject | Filibuvir | Small molecule | 300 mg | — |
| Subject | Filibuvir | Small molecule | 500 mg | — |